Skip to Primary Navigation

How tariffs are reshaping the US pharmaceutical industry

A man walks through a pharmacy in New York City.
Photo: Gary Hershorn/Getty Images

President Trump’s broad 10% tariff push spares pharma for now, but global supply chains may not stay immune.

When the storm hits, the worst course of action is to cling to the past, replaying “what ifs,” panicking over what should have been done, or wishing the winds would simply pass. Crises demand clarity, not nostalgia.

The first step is to see things exactly as they are: without illusion,

Get full access, free for a month

Start your 28-day free trial to continue reading and access
all content on GRIP – no payment details required.

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience